Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Recent progress in treatment for multiple sclerosis].

J Kira1

  • 1Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University.

Rinsho Shinkeigaku = Clinical Neurology
|July 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A nationwide survey of pediatric acquired demyelinating syndromes in Japan.

Neurology·2016
Same author

Body weight-based natalizumab treatment in adult patients with multiple sclerosis.

Journal of neurology·2015
Same author

Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population.

Modern rheumatology·2014
Same author

A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).

Multiple sclerosis (Houndmills, Basingstoke, England)·2013
Same author

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2012
Same author

Interleukin-7 receptor alpha gene polymorphism influences multiple sclerosis risk in Asians.

Neurology·2011
Same journal

[Let's present at a regional meeting].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Editor's Note].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Notice for Members].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[The Proceedings of the 250th Kyushu Regional Meeting of the Japanese Society of Neurology].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[The Proceedings of the 116th Tohoku Regional Meeting of the Japanese Society of Neurology].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Metagenomic analysis for central nervous system infections: clinical utility and future directions].

Rinsho shinkeigaku = Clinical neurology·2026
See all related articles

Multiple sclerosis (MS) treatment has new drugs, but specific therapies are needed. Research explores T cell vaccination, altered peptide ligands, and oral tolerance for targeted autoimmune disease management.

Area of Science:

  • Immunology
  • Neuroscience
  • Autoimmune Diseases

Context:

  • Multiple sclerosis (MS) is an autoimmune disease involving T helper 1 cells targeting myelin antigens.
  • Current MS treatments include non-specific immunomodulators like interferon-beta, copolymer 1, and IVIG.
  • These therapies reduce relapse rates, disease progression, and MRI lesion load.

Purpose:

  • To address the need for specific immunomodulation therapies in multiple sclerosis.
  • To explore novel therapeutic strategies beyond current non-specific treatments.
  • To investigate potential treatments for distinct MS subtypes, such as opticospinal MS prevalent in Asian populations.

Summary:

  • MS is an autoimmune disorder, with current treatments offering non-specific immunomodulation.

Related Experiment Videos

  • New therapeutic avenues like T cell vaccination, altered peptide ligands, and oral tolerance are being investigated for specific immune targeting.
  • The distinct HLA-DPB1*0501-associated opticospinal MS subtype in Asians necessitates unique therapeutic approaches.

    • Impact:

    • Highlights the limitations of current non-specific MS treatments.
    • Identifies promising specific immunotherapies for MS, including T cell vaccination, altered peptide ligands, and oral tolerance.
    • Emphasizes the importance of developing tailored therapies for specific MS subtypes like opticospinal MS.